ARTICLE | Company News
BioCryst, NIH infectious news
October 6, 2014 7:00 AM UTC
BioCryst said NIH's National Institute of Allergy and Infectious Disease (NIAID) exercised two additional options to provide $2 million to develop the company's BCX4430 to treat hemorrhagic fever viruses. The additional options will be used to provide GMP drug substance and drug product manufacture of BCX4430. ...